|
NYBA News |
Member News
|
Press Release
|
| |
|
|
News type
|
|
Pfizer Inc. |
|
Headline:
Pfizer to Acquire Excaliard Pharmaceuticals
Date:
22-Nov-2011
News Type:
Member News
Lead Program Includes Novel Investigational Compound for Prevention/Treatment of Skin
Scarring ...
Details »
|
|
| |
|
The Jackson Laboratory |
|
Headline:
New York Genome Center launches with The Jackson Laboratory, 10 other top biomedical institutions
Date:
13-Nov-2011
News Type:
Member News
New York, N.Y.—The Jackson Laboratory joins 10 top New York medical and academic
research institutes i ...
Details »
|
|
| |
|
New York Blood Center |
|
Headline:
FDA Approves New York Blood Center's HEMACORD(TM) for Stem Cell Transplantation
Date:
11-Nov-2011
News Type:
Member News
...
Details »
|
|
| |
|
Target Health Inc. |
|
Headline:
eSource Patent Issued to Target Health Inc
Date:
08-Nov-2011
News Type:
Member News
Target Health is pleased to announce that the United States Patent Office has issued US
Patent 8,041,581 for “System and Method for Collecting, Processing, and Storing
Discrete Data Records Based Upon a Single Data Input.“ This patent is part of Target
Health's commitment to the paperless clinical trial and the ...
Details »
|
|
| |
|
Pfizer Inc. |
|
Headline:
Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency
Date:
08-Nov-2011
News Type:
Member News
Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal
Urinary Urgency ...
Details »
|
|
| |
|
Genentech Inc. |
|
Headline:
FDA ACCEPTS GENENTECH’S NEW DRUG APPLICATION FOR VISMODEGIB IN ADVANCED FORM OF SKIN CANCER
Date:
08-Nov-2011
News Type:
Member News
-- The Vismodegib Application Has Been Granted Priority Review -- ...
Details »
|
|
| |
|
Genentech Inc. |
|
Headline:
DATA SHOWED ACTEMRA MONOTHERAPY SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
Date:
05-Nov-2011
News Type:
Member News
– X-ray Study Data Showed a Comparable Reduction in the Progression
of Structural ...
Details »
|
|
| |
|
Amgen, Inc. |
|
Headline:
Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
Date:
05-Nov-2011
News Type:
Member News
Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic
Therapy in Adults with Moderately Active RA
&nb ...
Details »
|
|
| |
|
Amgen, Inc. |
|
Headline:
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
Date:
05-Nov-2011
News Type:
Member News
Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the
open-label extension study of the pivotal Phase 3 fracture trial showing that six years of
Prolia® (denosumab) treatment in postmenopausal women with osteopor ...
Details »
|
|
| |
|
Genentech Inc. |
|
Headline:
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
Date:
19-Oct-2011
News Type:
Member News
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced
96-week results1 from a Phase II study of ocrelizumab in patients with relapsing-remitting
multiple sclero ...
Details »
|
|
| |
|
|
